Delisting risk
CEL-SCI
Develops a pre-surgical cytokine treatment for selected head-and-neck cancer patients.
$1.63
After-hours close+0.06 (+4.17%)
At close$1.56(−2.50%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 10.86%746.1K sharesInsiders 4.60%316.1K sharesOther 84.54%5.81M shares
Shares outstanding 6.87M · Float 6.31M · 91.9% free float
Institutions13F, as of Mar 31, 2026
37 holders · 746.1K shares · 5 new positions · 16 increased · 4 reduced · 7 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Vanguard Capital Management LLC | 243.6K | 3.55% | +243.6Knew | May 15, 2026 |
| Mai Capital Management | 91.3K | 1.33% | +1.6K | May 15, 2026 |
| Geode Capital Management, LLC | 85.3K | 1.24% | +6.1K | May 15, 2026 |
| Vanguard Fiduciary Trust Co | 49.0K | 0.71% | +49.0Knew | May 8, 2026 |
| BlackRock, Inc. | 43.3K | 0.63% | 0 | May 13, 2026 |
| Bank of America Corp /DE/ | 41.0K | 0.60% | +4 | May 18, 2026 |
| Renaissance Technologies LLC | 35.9K | 0.52% | +20.5K | May 14, 2026 |
| US Bancorp \DE\ | 29.9K | 0.44% | +11.5K | May 15, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Lincoln Alternative Strategies LLC | 6.94% | 555.0K | 13G | Aug 29, 2025 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Geert R. Kersten | director, officer: Chief Executive Officer | 316.1K | 4.60% | Aug 26, 2026 |
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 25, 2026 | Geert R. Kerstendirector, officer: Chief Executive Officer | Purchase | 100,000 | $1.38 | 316,142 |
CongressHouse and Senate disclosures
Not reported.